Shattuck Labs, Inc.

Shattuck Labs, Inc. (STTK) priced its initial public offering on Oct 13, 2020 at $17.00 per share, above its $14.00–$16.00 range, raising $202M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $679.4M. Gibson Dunn advised the company and Latham & Watkins advised the underwriters.

Shattuck Labs, Inc. is a clinical-stage biotechnology company developing dual-sided fusion proteins, a new class of biologic. Its Agonist Redirected Checkpoint (ARC) platform produces compounds that inhibit checkpoint molecules and activate costimulatory molecules at once, with SL-172154 as the lead candidate for immuno-oncology.

Status

IPO

Ticker

STTK

Exchange

Nasdaq Global Select

Priced

Oct 13, 2020

IPO price

$17.00

Price range

$14.00–$16.00

Raised

$202M

Market cap at IPO price

$679.4M

First filed

Sep 18, 2020

Company counsel

Gibson Dunn

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

TX

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.